Literature DB >> 25108021

The role of metalloproteinase ADAM17 in regulating ICOS ligand-mediated humoral immune responses.

Joanna Marczynska1, Aleksandra Ozga1, Agnieszka Wlodarczyk1, Monika Majchrzak-Gorecka1, Paulina Kulig1, Magdalena Banas1, Dominika Michalczyk-Wetula2, Pawel Majewski1, Andreas Hutloff3, Jeanette Schwarz4, Athena Chalaris4, Jürgen Scheller5, Stefan Rose-John4, Joanna Cichy6.   

Abstract

Immune cells regulate cell surface receptor expression during their maturation, activation, and motility. Although many of these receptors are regulated largely at the level of expression, protease-mediated ectodomain shedding represents an alternative means of refashioning the surface of immune cells. Shedding is largely attributed to a family of a disintegrin and metalloprotease domain (ADAM) metalloproteases, including ADAM17. Although ADAM17 is well known to contribute to the innate immune response, mainly by releasing TNF-α, much less is known about whether/how this metalloprotease regulates adaptive immunity. To determine whether ADAM17 contributes to regulating adaptive immune responses, we took advantage of ADAM17 hypomorphic (ADAM17(ex/ex)) mice, in which ADAM17 expression is reduced by 90-95% compared with wild-type littermates. In this study, we show that that ADAM17 deficiency results in spleen and lymph node enlargement, as well as increased levels of Ag-specific class-switched Ig production following immunization with OVA together with anti-CD40 mAbs and polyinosinic-polycytidylic acid. Moreover, we demonstrate that the costimulatory ligand ICOS ligand (ICOSL) is selectively downregulated on the surface of B cells in an ADAM17-specific manner, although it is not proteolitically processed by recombinant ADAM17 in vitro. Finally, we show that higher cell surface levels of ICOSL in ADAM17(ex/ex) mice may contribute to the development of excessive Ab responses. Therefore, our data suggest a functional link between ADAM17 and ICOSL in controlling adaptive immune responses.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25108021     DOI: 10.4049/jimmunol.1302893

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  B cell ADAM17 controls T cell independent humoral immune responses through regulation of TACI and CD138.

Authors:  Joseph C Lownik; Jessica L Wimberly; Leila Takahashi-Ruiz; Rebecca K Martin
Journal:  Biochem Biophys Res Commun       Date:  2019-11-23       Impact factor: 3.575

2.  B Cell ADAM10 Controls Murine Lupus Progression through Regulation of the ICOS:ICOS Ligand Axis.

Authors:  Joseph C Lownik; Jessica L Wimberly; Daniel H Conrad; Rebecca K Martin
Journal:  J Immunol       Date:  2019-01-04       Impact factor: 5.422

3.  ADAM10-Mediated ICOS Ligand Shedding on B Cells Is Necessary for Proper T Cell ICOS Regulation and T Follicular Helper Responses.

Authors:  Joseph C Lownik; Andrea J Luker; Sheela R Damle; Lauren Folgosa Cooley; Riham El Sayed; Andreas Hutloff; Costantino Pitzalis; Rebecca K Martin; Mohey Eldin M El Shikh; Daniel H Conrad
Journal:  J Immunol       Date:  2017-08-16       Impact factor: 5.422

4.  The role of ADAM17 in the T-cell response against bacterial pathogens.

Authors:  Moritz Andreas Link; Karsten Lücke; Joanna Schmid; Valéa Schumacher; Thomas Eden; Stefan Rose-John; Hans-Willi Mittrücker
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

5.  Human CD6 Down-Modulation following T-Cell Activation Compromises Lymphocyte Survival and Proliferative Responses.

Authors:  Esther Carrasco; Cristina Escoda-Ferran; Núria Climent; Cristina Miró-Julià; Inês T Simões; Mario Martínez-Florensa; Adelaida Sarukhan; Esther Carreras; Francisco Lozano
Journal:  Front Immunol       Date:  2017-06-30       Impact factor: 7.561

Review 6.  Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation.

Authors:  Marcia L Moss; Dmitry Minond
Journal:  Mediators Inflamm       Date:  2017-11-02       Impact factor: 4.711

7.  T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival.

Authors:  Catherine A Bonham; Cara L Hrusch; Kelly M Blaine; Stephenie T Manns; Rekha Vij; Justin M Oldham; Matthew M Churpek; Mary E Strek; Imre Noth; Anne I Sperling
Journal:  Respir Med X       Date:  2019-02-01

8.  Adenosine monophosphate deaminase 3 null mutation causes reduction of naive T cells in mouse peripheral blood.

Authors:  Xiaoming Zhan; Xue Zhong; Jin Huk Choi; Lijing Su; Jianhui Wang; Evan Nair-Gill; Priscilla Anderton; Xiaohong Li; Miao Tang; Jamie Russell; Sara Ludwig; Thomas Gallagher; Bruce Beutler
Journal:  Blood Adv       Date:  2020-08-11

9.  EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells.

Authors:  Jianhua Li; Erick Lu; Tangsheng Yi; Jason G Cyster
Journal:  Nature       Date:  2016-05-05       Impact factor: 49.962

10.  Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF.

Authors:  Shanna L Ashley; Meng Xia; Susan Murray; David N O'Dwyer; Ethan Grant; Eric S White; Kevin R Flaherty; Fernando J Martinez; Bethany B Moore
Journal:  PLoS One       Date:  2016-08-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.